Premium
Treatment concerns for bullous pemphigoid in the COVID ‐19 pandemic era
Author(s) -
Azimi Seyyede Zeinab,
Firooz Alireza,
Murrell Dedee F.,
Daneshpazhooh Maryam
Publication year - 2020
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.13956
Subject(s) - medicine , pandemic , bullous pemphigoid , covid-19 , outbreak , coronavirus , pemphigoid , disease , immunology , dermatology , virology , intensive care medicine , infectious disease (medical specialty) , antibody
Bullous pemphigoid (BP) is the most common autoimmune blistering disease with subepidermal involvement, typically affecting the elderly. It has spontaneous remissions and exacerbations with significant morbidity. A novel coronavirus called severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) is responsible for the new universal coronavirus disease 2019 (COVID‐19) pandemic. The pandemic made concerns, especially about immunosuppressive therapy. In this article, we reviewed the management of BP in the COVID‐19 pandemic era. The data about the best management of autoimmune bullous diseases like BP, during the outbreak of COVID‐19, are evolving and updated every day.